UK markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.9300+0.0900 (+3.17%)
As of 03:59PM EDT. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-74,385
-72,849
-69,456
-76,247
-63,745
Depreciation & amortisation
1,425
1,404
1,427
1,753
1,978
Deferred income taxes
-
-
-
-
0
Stock-based compensation
9,184
9,301
7,182
6,424
6,161
Change in working capital
-8,758
-18,233
29,243
925
431
Accounts receivable
525
-424
-453
413
-108
Accounts payable
-
-
5,216
1,911
1,666
Other working capital
-78,916
-86,944
-35,868
-68,341
-51,670
Other non-cash items
-3,012
-3,343
-3,698
-1,386
1,035
Net cash provided by operating activities
-77,930
-85,936
-35,356
-67,532
-51,441
Cash flows from investing activities
Investments in property, plant and equipment
-986
-1,008
-512
-809
-229
Acquisitions, net
-
-
-
-
-2,500
Purchases of investments
-85,701
-80,509
-130,430
-82,219
-85,578
Sales/maturities of investments
-
132,270
56,000
70,350
73,398
Other investing activities
-
-
-
-
-12,180
Net cash used for investing activities
45,789
50,773
-74,942
-12,678
-14,909
Cash flows from financing activities
Common stock issued
31,755
29,852
20,324
134,665
86,297
Net cash used provided by (used for) financing activities
34,660
30,647
31,814
137,236
86,746
Net change in cash
2,527
-4,491
-78,506
57,031
20,452
Cash at beginning of period
40,574
30,776
109,282
52,251
31,799
Cash at end of period
43,093
26,285
30,776
109,282
52,251
Free cash flow
Operating cash flow
-77,930
-85,936
-35,356
-67,532
-51,441
Capital expenditure
-986
-1,008
-512
-809
-229
Free cash flow
-78,916
-86,944
-35,868
-68,341
-51,670